CLAIMS

1. Use of a combination comprising at least two chemotherapy agents and a dose of a composition consisting essentially of attenuated *Salmonella typhimurium* in the manufacture of a medicament for treating a solid tumor cancer.

2. The use of claim 1 wherein the at least two chemotherapy agents comprise gemcitabine and capecitabine.

3. The use of claim 1 wherein the at least two chemotherapy agents comprise two or more of leucovorin, 5-fluorouracil, irinotecan, and oxaliplatin.

4. The use of claim 3 wherein the at least two chemotherapy agents comprise each of leucovorin, 5-fluorouracil, irinotecan, and oxaliplatin.

5. The use of any of claims 1-4 wherein the solid tumor cancer is selected from liver cancer, lung cancer, pancreatic cancer, breast cancer, prostate cancer, skin cancer, kidney cancer, bone cancer, gastrointestinal cancers, cancers of the soft tissue, muscle cancer, adrenal cancer, colon cancer, and bladder cancer.

6. The use of claim 5 wherein the solid tumor cancer is pancreatic cancer.

7. The use of any of claims 1-6 wherein the at least two chemotherapy agents are to be administered intravenously or orally.

8. The use of any of claims 1-7 wherein the dose of attenuated *Salmonella typhimurium* is to be administered orally.

9. The use of any of claims 1-8 wherein the subject is a mammal.

10. The use of claim 9 wherein the mammal is a human.

11. The use of any of claims 1-10 wherein the dose of attenuated *Salmonella typhimurium* is from 10^5 to 10^{10} colony forming units.

12. The use of any of claims 1-11 wherein the solid tumor cancer is a metastatic cancer.

13. The use of any of claims 1-12 wherein the at least two chemotherapy agents and/or the attenuated *Salmonella typhimurium* is to be administered to the subject every two to four weeks.

14. Use of a combination comprising at least two chemotherapy agents and a dose of a composition consisting essentially of attenuated *Salmonella typhimurium* containing a plasmid carrying a coding sequence encoding a truncated human interleukin-2, wherein the truncated human interleukin-2 consists of the amino acid sequence shown in SEQ ID NO: 2, in the manufacture of a medicament for treating a solid tumor cancer.

15. The use of claim 14 wherein the at least two chemotherapy agents comprise gemcitabine and capecitabine.

16. The use of claim 14 wherein the at least two chemotherapy agents comprise two or more of leucovorin, 5-fluorouracil, irinotecan, and oxaliplatin.

17. The use of claim 16 wherein the at least two chemotherapy agents comprise each of leucovorin, 5-fluorouracil, irinotecan, and oxaliplatin.

18. The use of claim any of claims 14-17 wherein the solid tumor cancer is selected from liver cancer, lung cancer, pancreatic cancer, breast cancer, prostate cancer, skin cancer, kidney cancer, bone cancer, gastrointestinal cancers, cancers of the soft tissue, muscle cancer, adrenal cancer, colon cancer, and bladder cancer.

19. The use of claim 18 wherein the solid tumor cancer is pancreatic cancer.

20. The use of any of claims 14-19 wherein the at least two chemotherapy agents are to be administered intravenously or orally.

21. The use of any of claims 14-20 wherein the dose of attenuated *Salmonella typhimurium* is to be administered orally.

22. The use of any of claims 14-21 wherein the subject is a mammal.

23. The use of claim 22 wherein the mammal is a human.

24. The use of any of claims 14-23 wherein the dose of attenuated *Salmonella typhimurium* is from 10^5 to 10^{10} colony forming units.

25. The use of any of claims 14-24 wherein the solid tumor cancer is a metastatic cancer.

26. The use of any of claims 14-25 wherein the at least two chemotherapy agents and/or the attenuated *Salmonella typhimurium* is to be administered to the subject every two to four weeks.

27. Use of an anti-tumor agent comprising a combination comprising at least two chemotherapy agents and a dose of a composition consisting essentially of attenuated *Salmonella typhimurium* containing a plasmid carrying a coding sequence encoding a truncated human interleukin-2, wherein the truncated human interleukin-2 consists of the amino acid sequence shown in SEQ ID NO: 2, in the manufacture of a medicament for treating a solid tumor cancer.

28. The use of claim 27 wherein the at least two chemotherapy agents comprise gemcitabine and capecitabine.

29. The use of claim 27 wherein the at least two chemotherapy agents comprise two or more of leucovorin, 5-fluorouracil, irinotecan, and oxaliplatin.

30. The use of claim 29 wherein the at least two chemotherapy agents comprise each of leucovorin, 5-fluorouracil, irinotecan, and oxaliplatin.

31. The use of any of claims 27-30 wherein the solid tumor cancer is selected from liver cancer, lung cancer, pancreatic cancer, breast cancer, prostate cancer, skin cancer, kidney

cancer, bone cancer, gastrointestinal cancers, cancers of the soft tissue, muscle cancer, adrenal cancer, colon cancer, and bladder cancer.

32. The use of claim 31 wherein the solid tumor cancer is pancreatic cancer.

33. The use of any of claims 27-32 wherein the at least two chemotherapy agents are to be administered intravenously or orally.

34. The use of any of claims 27-33 wherein the dose of attenuated *Salmonella typhimurium* is to be administered orally.

35. The use of any of claims 27-34 wherein the subject is a mammal.

36. The use of claim 35 wherein the mammal is a human.

37. The use of any of claims 27-36 wherein the dose of attenuated *Salmonella typhimurium* is from 10^5 to 10^{10} colony forming units.

38. The use of any of claims 27-37 wherein the solid tumor cancer is a metastatic cancer.

39. The use of any of claims 27-38 wherein the at least two chemotherapy agents and/or the attenuated *Salmonella typhimurium* is to be administered to the subject every two to four weeks.

40. Use of a combination comprising at least two chemotherapy agents and a dose of a composition consisting essentially of attenuated *Salmonella typhimurium* containing a plasmid carrying a coding sequence encoding a truncated human interleukin-2, wherein the truncated human interleukin-2 consists of the amino acid sequence shown in SEQ ID NO: 2, wherein the at least two chemotherapy agents comprise leucovorin, 5-fluorouracil, irinotecan, and oxaliplatin, in the manufacture of a medicament for treating pancreatic cancer.